BioVie
$0.44 -0.0285 -6.14% 341.9K
Company Overview
BioVie is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation that leads to neuroinflammation, and insulin resistance believed to be drivers of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis.
Value Proposition
BioVie is strategically positioned for significant value creation, supported by a robust cash position and a series of anticipated catalysts over the next 18 months and beyond. Key upcoming catalysts include the launch of the Parkinson’s Phase 2b trial in Fall 2024 and the next Alzheimer’s Phase 3 trial using a new once-daily formulation of bezisterim in mid-2025. Additionally, ongoing partnership discussions for bezisterim's geographic rights and the planned launch of an ascites Phase 3 trial upon securing a partner further support the investment case for BioVie.
Far-reaching impact of TNFα-mediated chronic low-grade inflammation
Investor Presentation
Investment Highlights
-
Lead asset bezisterim (formerly NE3107) modulates the production of TNFα.
In clinical trials, many patients treated with bezisterim experienced:
- Reduced inflammation and the associated insulin resistance
- Improved motor control and “morning on” symptoms in PD
- Improved cognition and function, lowered amyloid β and p-tau levels, and improved brain imaging scans in AD
- Lowered DNA methylation levels
-
Significant unmet medical needs in PD & AD
- $30+ billion annual peak sales potential in PD for bezisterim.
- $3+ billion annual peak sales potential in AD for bezisterim.
-
Among competitive molecules exploring neuroinflammation, bezisterim is the
only one that:
- Has published randomized, double-blinded, placebo Phase 2 results potentially suggesting reduction in inflammation and insulin resistance in a major population
- Potentially inhibits proinflammatory pathways without impacting homeostasis.
- Awarded $13.1 million grant from Department od Defense to explore Bezisterim in long Covid
-
BIV201 is the only drug currently in development for refractory ascites, a
condition with 50% mortality rate. It has the potential to become first therapy
since there are no approved drugs in the US
- BIV201 is a novel formulation of terlipressin for continuous infusion; Orphan and Fast Track designations received.
- Discussions with FDA following encouraging data from Phase 2b study enabled finalization of design for pivotal registration trial.
- $1.6 billion global peak sales potential.
-
Upcoming catalysts
- Launch Parkinson’s Phase 2b trial Fall 2024
- Launch next Alzheimer’s Phase 3 trial in mid-2025 using new once-daily formulation of bezisterim
- Continue partnering conversations for bezisterim (geographic rights)
- Launch ascites Phase 3 when partner identified
Commercial Potential in US Market
